Search
Enzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Gluconolactone
go.drugbank.com/drugs/DB04564ApprovedGluconolactone is a naturally-occurring food additive used as a sequestrant, an acidifier, or a curing, pickling, or leavening agent. It is a cyclic ester of D-gluconic acid.
Synonyms: 1,5-D-gluconolactone, D-glucono-1,5-lactonePivhydrazine
go.drugbank.com/drugs/DB09252ApprovedWithdrawnIn 1960, it was widely used as an antidepressant agent but it is now discontinued.
Egg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
SL017
go.drugbank.com/drugs/DB05156ExperimentalSL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigational[A232955, A232960] In September 2023, the FDA also approved cipaglucosidase alfa for similar indications.[L49241]
LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.
Synonyms: BoNT/A-DSFlorquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease